Related news from
Tue, 09 Apr 2024 12:01:00 +0000	Xencor Appoints Bart Cornelissen as Chief Financial Officer PASADENA, Calif., April 09, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance at
Fri, 08 Mar 2024 22:01:38 +0000	Insider Sell: SR. VICE PRESIDENT & CFO John Kuch Sells 4,474 Shares of Xencor Inc (XNCR) John Kuch, Senior Vice President & Chief Financial Officer of Xencor Inc (NASDAQ:XNCR), has sold 4,474 shares of the company on March 5, 2024, according to a recent SEC filing.
Thu, 07 Mar 2024 22:00:51 +0000	Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR) Bassil Dahiyat, President & CEO of Xencor Inc (NASDAQ:XNCR), sold 12,528 shares of the company on March 5, 2024, according to a recent SEC Filing.
Thu, 29 Feb 2024 10:33:39 +0000	Xencor Full Year 2023 Earnings: Misses Expectations Xencor ( NASDAQ:XNCR ) Full Year 2023 Results Key Financial Results Revenue: US$168.3m (up 2.3% from FY 2022). Net...
Wed, 28 Feb 2024 21:01:00 +0000	Xencor to Present at Upcoming Investor Conferences PASADENA, Calif., February 28, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:
Wed, 28 Feb 2024 14:35:03 +0000	Q4 2023 Xencor Inc Earnings Call Q4 2023 Xencor Inc Earnings Call
Wed, 28 Feb 2024 13:38:16 +0000	Xencor, Inc. (NASDAQ:XNCR) Q4 2023 Earnings Call Transcript Xencor, Inc. (NASDAQ:XNCR) Q4 2023 Earnings Call Transcript February 28, 2024 Xencor, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and thank you for standing by. Welcome to Xencor’s Fourth Quarter and Year End 2023 Conference Call. […]
Tue, 27 Feb 2024 22:20:07 +0000	Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates Xencor (XNCR) delivered earnings and revenue surprises of -186.11% and 68.25%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Tue, 27 Feb 2024 21:39:17 +0000	Xencor Inc (XNCR) Reports Mixed Financial Results for Q4 and Full Year 2023 Encouraging Clinical Data Accompanies Financial Update
Tue, 27 Feb 2024 21:01:00 +0000	Xencor Reports Fourth Quarter and Full Year 2023 Financial Results PASADENA, Calif., February 27, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a review of recent business and clinical highlights. The Company also presented encouraging early clinical data from its Phase 2 study of vudalimab monotherapy for patients with clinically defined
Tue, 20 Feb 2024 21:31:00 +0000	Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update PASADENA, Calif., February 20, 2024--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2023 after the market closes on Tuesday, February 27, 2024.
Mon, 19 Feb 2024 08:37:00 +0000	Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains? Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Thu, 15 Feb 2024 15:00:40 +0000	Xencor (XNCR) Earnings Expected to Grow: What to Know Ahead of Q4 Release Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wed, 03 Jan 2024 21:01:00 +0000	Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference PASADENA, Calif., January 03, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 at 3:45 p.m. PST.
Wed, 03 Jan 2024 14:55:00 +0000	Xencor (XNCR) Soars 6.0%: Is Further Upside Left in the Stock? Xencor (XNCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Tue, 02 Jan 2024 13:01:00 +0000	Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy PASADENA, Calif., January 02, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Dane Leone, CFA, has joined Xencor as senior vice president, corporate strategy. In this newly created role, Mr. Leone will support the Company’s R&D leadership to enhance value across Xencor’s platform technologies by overseeing assessment and prioritization of Xencor’s
Sat, 30 Dec 2023 22:02:03 +0000	Insider Sell: Xencor Inc President & CEO Bassil Dahiyat Sells 45,000 Shares On December 29, 2023, Bassil Dahiyat, President & CEO of Xencor Inc (NASDAQ:XNCR), executed a sale of 45,000 shares of the company.
Sun, 10 Dec 2023 12:04:44 +0000	Xencor (NASDAQ:XNCR) shareholders are up 7.7% this past week, but still in the red over the last three years Xencor, Inc. ( NASDAQ:XNCR ) shareholders should be happy to see the share price up 19% in the last month. But that is...
Tue, 21 Nov 2023 21:01:00 +0000	Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference PASADENA, Calif., November 21, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced that company management will present at the Piper Sandler 35th Annual Healthcare Conference in New York City on Tuesday, November 28, 2023, at 8:00 a.m. ET / 11:00 a.m. PT.
Mon, 13 Nov 2023 10:02:29 +0000	Things Look Grim For Xencor, Inc. (NASDAQ:XNCR) After Today's Downgrade One thing we could say about the analysts on Xencor, Inc. ( NASDAQ:XNCR ) - they aren't optimistic, having just made a...